CymaBay Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
-
10,000.00
105
Cost of Goods Sold (COGS) incl. D&A
55.00
18.00
22.00
29.00
-
105
Gross Income
55.00
18.00
22.00
29.00
-
105
SG&A Expense
9,341.00
23,990.00
25,875.00
25,557.00
31,290.00
72,400
EBIT
9,396.00
24,008.00
25,897.00
25,586.00
21,325.00
72,505
Unusual Expense
494.00
14,436.00
11,121.00
76.00
5,773.00
407
Non Operating Income/Expense
629.00
7,208.00
-
-
-
3,288
Interest Expense
822.00
755.00
913.00
1,337.00
1,080.00
336
Pretax Income
10,073.00
31,917.00
15,529.00
26,671.00
27,557.00
72,548
Consolidated Net Income
243,994.00
31,917.00
15,529.00
26,671.00
27,557.00
72,548
Net Income
243,994.00
31,917.00
15,529.00
26,671.00
27,557.00
72,548
Net Income After Extraordinaries
243,994.00
31,917.00
15,529.00
26,671.00
27,557.00
72,548
Net Income Available to Common
243,994.00
31,917.00
15,529.00
26,671.00
27,557.00
72,548
EPS (Basic)
3.54
2.65
0.83
1.14
0.79
1.25
Basic Shares Outstanding
2,357.00
12,049.00
18,900.50
23,447.00
34,904.00
57,808.30
EPS (Diluted)
3.54
2.65
0.83
1.14
0.79
1.25
Diluted Shares Outstanding
2,845.60
12,049.00
18,900.50
23,447.00
34,904.00
57,808.30
EBITDA
9,341.00
23,990.00
25,875.00
25,557.00
21,290.00
72,400
Non-Operating Interest Income
10.00
74.00
160.00
176.00
621.00
3,988
Other After Tax Income (Expense)
254,067.00
-
-
-
-
-
About CymaBay Therapeutics
View Profile
